UK Edition. Click here for US version.
BOOTS MUCUS COUGH RELIEF 100MG/5ML ORAL SOLUTION
Active substance(s): GUAIPHENESIN
NAME OF THE MEDICINAL PRODUCT
Boots Chesty Cough Relief 100 mg/5ml Oral Solution
Boots Mucus Cough Relief 100mg/5ml Oral Solution
QUALITATIVE AND QUANTITATIVE COMPOSITION
Guaifenesin Ph Eur
An expectorant for the relief of chesty coughs.
Posology and method of administration
Adults and children over 12 years:
Two 5ml spoonfuls every four hours up to four times a day.
Children under 12 years:
There is no need for dosage reduction in the elderly.
Hypersensitivity to the active substance or any of the excipients.
Special warnings and precautions for use
Not recommended for children under 12 years.
Do not exceed the stated dose.
Ask a doctor before use if you suffer from a chronic cough, if you have asthma or are
suffering from an acute asthma attack.
Stop use and ask a healthcare professional if your cough lasts for more than 5 days,
comes back, or is accompanied by a fever, rash or persistent headache.
Do not take with a cough suppressant.
Keep all medicines out of the reach of children.
Interaction with other medicinal products and other forms of interaction
There are no clinically significant interactions.
If urine is collected within 24 hours of a dose of guaifenesin a metabolite of
guaifenesin may cause a colour interference with laboratory determinations of urinary
5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
Pregnancy and Lactation
The safety of this product during pregnancy and lactation has not been
established. However guaiphenesin is not considered to constitute a hazard
during pregnancy since there is no evidence of an association with foetal
malformations. There is no data available on use of guaiphenesin during
Effects on Ability to Drive and Use Machines
No adverse effects known.
The following side effects may be associated with the use of guaifenesin:
Gastrointestinal disorders: nausea, vomiting/gastrointestinal discomfort.
Immune system disorder: hypersensitivity reactions, including anaphylaxis.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk
balance of the medicinal product. Healthcare professionals are asked to report
any suspected adverse reactions via the Yellow Card Scheme at
Overdosage may give rise to nausea and vomiting.
Treatment need only be symptomatic and supportive.
Guaifenesin reduces the viscosity of tenacious sputum and is used as an
Guaifenesin is readily absorbed from the gastrointestinal tract. It is
metabolised and excreted in the urine.
Pre-clinical Safety Data
List of excipients
Flav F menthol E43525
Citric acid monohydrate
Food flavour 511630E TM
Special Precautions for Storage
Do not store above 25°C.
Do not refrigerate or freeze.
Nature and Content of Container
An amber PET bottle with a polypropylene child resistant cap fitted with an
expanded polyethylene liner.
Pack size: 150ml, 240ml, 300ml
Special precautions for disposal
MARKETING AUTHORISATION HOLDER
The Boots Company PLC
1 Thane Road West
Nottingham NG2 3AA
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
DATE OF REVISION OF THE TEXT
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.